Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Scrip AMR Round Table Part 1: Green Shoots After Long Winter

Executive Summary

In a round table discussion held on the sidelines of the ECCMID conference in Amsterdam in April 2016, a panel of experts offered their perspectives on the problem of antimicrobial resistance, and what it will take to protect the world's population from this threat.

In Part 1, the panelists discuss the findings of the UK's O'Neill Commission, the costs of doing nothing, some specific public health interventions and the slow but real increase in engagement both at a political level and at an industry level.

The round table was chaired by Scrip Editor Eleanor Malone, and the panelists were:

  • John Rex, Senior Vice-President and Chief Strategy Officer for AstraZeneca's antibiotics business unit.
  • Professor Mike Sharland, Professor of Paediatric Infectious Disease at St George's University Hospital and Chair of a government Expert Advisory Committee on AMR for England.
  • Roman Kozlov, Chief Specialist at the Ministry of Health of the Russian Federation in Clinical Microbiology and Antimicrobial Resistance, and a Director at the Institute of Antimicrobial Chemotherapy at the Smolensk State Medical University.
  • Matteo Bassetti, head of Infectious Diseases Division of the Santa Maria Misericordia University Hospital in Udine, Italy, and Professor of Infectious Diseases at the School of Medicine and Postgraduate School of Infectious Diseases at the University of Udine.

This Round Table was hosted by Scrip with sponsorship from AstraZeneca.

Advertisement

Related Content

Scrip AMR Round Table Part 2: We Need More Numbers
Jim O'Neill Optimistic His AMR Review Won't Run Into The Sand
AstraZeneca, Allergan Sign Another Antibiotic Pact
Will Industry's General Pledges On AMR And Calls For Government Cash Cut It At Davos?

Topics

Advertisement
UsernamePublicRestriction

Register

SC065191

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel